Lester Cathy, Lubey Gwen, Dicks Michael, Andol Gregory, Vaughn Dana, Cambron R Thomas, Poiesz Katherine, Redman-Furey Nancy
Analytical Department, Procter & Gamble Pharmaceuticals, Inc., Mason, Ohio, USA.
J Pharm Sci. 2006 Dec;95(12):2631-44. doi: 10.1002/jps.20662.
Dehydration of hydrates of pharmaceutical active ingredients (pharmaceutical hydrates) may easily occur during storage or manufacturing. Loss of water may have little effect on the crystal lattice, produce less hydrated forms or possibly amorphous forms. Characterizing the effects of water loss on crystal hydrate forms is important for understanding the behavior of pharmaceutical hydrates throughout the manufacturing and storage processes. This study shows that exposure of the hemi-pentahydrate form of risedronate monosodium to gentle heating (60 degrees C) or conditions of low relative humidity (<10% RH) results in the loss of 1 mole of channel-type water. Upon removal of the channel-type water, the crystal lattice adjusts producing a distinct phase characterized by X-ray, thermal, IR, Raman, and NMR data. Adjustment of the crystal lattice appears to compromise crystal integrity and can result in reduced crystallite and particle sizes.
药物活性成分水合物(药用氢氧化物)在储存或制造过程中可能很容易发生脱水。水分流失可能对晶格影响很小,产生较少水合形式或可能产生无定形形式。表征水分流失对晶体水合物形式的影响对于理解药用氢氧化物在整个制造和储存过程中的行为非常重要。本研究表明,将单水合利塞膦酸钠的半五水合物形式置于温和加热(60摄氏度)或低相对湿度(<10%RH)条件下,会导致1摩尔通道型水的流失。除去通道型水后,晶格会进行调整,产生一种由X射线、热、红外、拉曼和核磁共振数据表征的独特相。晶格的调整似乎会损害晶体完整性,并可能导致微晶和颗粒尺寸减小。